InfuSystem (INFU) to release 2025 results and host investor call Feb. 24
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
InfuSystem Holdings, Inc. filed a current report announcing the timing of its upcoming financial disclosure. The company plans to release preliminary fourth quarter and full-year 2025 results on February 24, 2026 before the market opens.
InfuSystem will host an investor conference call on the same day at 9:00 a.m. Eastern Time to discuss these results, with both live webcast access and a telephone replay available through early March. The filing clarifies that the related press release is furnished under Regulation FD and is not deemed filed for liability purposes.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 17, 2026
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices) (Zip Code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
| Not Applicable | ||||||||
| (Former Name or Former Address, if Changed Since Last Report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 - Regulation FD
On February 17, 2026 , InfuSystem Holdings, Inc. (the “Company”) issued a press release announcing that the Company will disclose its preliminary financial results for the fourth quarter and fiscal year 2025 on Tuesday, February 24, 2026 before the market opens. The Company will also conduct a conference call for all interested investors on Tuesday, February 24, 2026 at 9:00 a.m. Eastern Time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 7.01 — “Regulation FD Disclosure” of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
99.1 | Press Release of InfuSystem Holdings, Inc. dated February 17, 2026 | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INFUSYSTEM HOLDINGS, INC. | |||||
By: | /s/ Carrie Lachance | ||||
| Carrie Lachance | |||||
| Chief Executive Officer and Director | |||||
Dated: 2/17/2026
Exhibit 99.1
 | InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 248-291-1210 | ||||
FOR IMMEDIATE RELEASE
CONTACT: Barry Steele
Chief Financial Officer
248-260-2211
InfuSystem to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Investor Conference Call to be held 9:00 a.m. Eastern Time
Rochester Hills, Michigan, February 17, 2026 — InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it will issue preliminary fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the market opens.
The Company will also conduct a conference call for all interested parties on Tuesday, February 24, 2026 at 9:00 a.m. Eastern Time to discuss its financial results.
To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ or by calling (855) 669-9658 or (412) 317-0088, replay access code 5092611 through Tuesday, March 3, 2026.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.
####
FAQ
When will InfuSystem (INFU) report its Q4 and full-year 2025 results?
InfuSystem plans to release preliminary fourth quarter and full-year 2025 financial results on February 24, 2026 before the market opens. This timing lets investors review the figures ahead of the company’s scheduled conference call later that morning.
Is InfuSystem (INFU) holding an earnings conference call for 2025 results?
Yes. InfuSystem will host an investor conference call on February 24, 2026 at 9:00 a.m. Eastern Time. Investors can join by phone or through a live webcast in the Investors section of the company’s website.
How can investors access InfuSystem’s (INFU) Q4 2025 earnings call replay?
A replay of InfuSystem’s earnings call will be available via the company’s investor relations website and by phone. Telephone replay can be accessed using replay code 5092611 through March 3, 2026, allowing investors to review the discussion later.
What type of company is InfuSystem Holdings, Inc. (INFU)?
InfuSystem is a national healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers. It operates two platforms, Patient Services and Device Solutions, supporting oncology, pain management, wound therapy, rentals, equipment sales, and biomedical services.
Where is InfuSystem (INFU) headquartered and where does it operate?
InfuSystem is headquartered in Rochester Hills, Michigan. It delivers local, field-based customer support and operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada, supporting its Patient Services and Device Solutions platforms.
On which exchange is InfuSystem (INFU) listed and what is its stock symbol?
InfuSystem’s common stock is listed on the NYSE American under the trading symbol INFU. The company’s shares have a par value of $0.0001 per share, as indicated in the registration details.